Choreo LLC Increases Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Choreo LLC boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 29.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,274 shares of the life sciences company’s stock after acquiring an additional 5,123 shares during the period. Choreo LLC’s holdings in Integra LifeSciences were worth $500,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. KBC Group NV boosted its stake in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in Integra LifeSciences by 6.5% in the third quarter. Exchange Traded Concepts LLC now owns 33,403 shares of the life sciences company’s stock worth $607,000 after buying an additional 2,036 shares during the period. New York State Teachers Retirement System boosted its position in Integra LifeSciences by 3.0% during the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock valued at $1,637,000 after acquiring an additional 2,616 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth approximately $73,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on IART. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Citigroup upped their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Trading Up 0.4 %

NASDAQ IART opened at $25.68 on Wednesday. The stock’s fifty day moving average price is $23.85 and its 200-day moving average price is $21.84. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market cap of $1.98 billion, a P/E ratio of -285.30, a P/E/G ratio of 0.87 and a beta of 1.17. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.